The Epidermolysis Bullosa market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Epidermolysis Bullosa: An Overview
Epidermolysis Bullosa (EB) is a group of skin diseases that cause various degrees of skin and mucous membrane fragility. The skin becomes fragile when proteins essential for skin integrity are absent, reduced, or abnormal. It is characterized by blister formation in response to mechanical trauma.
To date, there is no treatment or cure for Epidermolysis Bullosa. EB is generally caused by mutations involving at least 18 genes encoding structural proteins within keratin intermediate filaments, focal adhesions, desmosome cell junctions, and hemidesmosome attachment complexes, which form the intraepidermal adhesion and dermo-epidermal anchoring complex within the basement membrane zone (BMZ) of the skin and mucosae.
Epidermolysis Bullosa Market Key Facts
The total diagnosed prevalent cases of Epidermolysis Bullosa in the 7MM was estimated to be 39,400+ in 2017.
In the United States, there were 26,100+ prevalent cases of Epidermolysis Bullosa in 2017.
Among the European countries, the United Kingdom had the highest prevalent population of Epidermolysis Bullosa with 5,000+ cases, followed by Germany which had a prevalent population of 4,900+ in 2017. On the other hand, Spain had the lowest prevalent population of 900+ in 2017.
Epidermolysis Bullosa Market
The Epidermolysis Bullosa (EB) market size in the 7MM is expected to increase during the forecast period. The United States accounts for the highest market size of Epidermolysis Bullosa, in comparison to the other major markets i.e., EU5 countries (the United Kingdom, Germany, Italy, France, and Spain), and Japan. Similarly, among the EU5 countries, the UK had the highest market size, while Spain had the lowest market size of Epidermolysis Bullosa in 2017.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Epidermolysis Bullosa market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Epidermolysis Bullosa market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Epidermolysis Bullosa Epidemiology
The epidemiology section covers insights about the historical and current Epidermolysis Bullosa patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Epidermolysis Bullosa Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Epidermolysis Bullosa market or expected to get launched in the market during the study period. The analysis covers Epidermolysis Bullosa market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Epidermolysis Bullosa Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/epidermolysis-bullosa-market
Epidermolysis Bullosa Therapeutics Analysis
Epidermolysis Bullosa (EB) market size in the 7MM is expected to change in the coming years owing to the launch of emerging therapies.
Epidermolysis Bullosa Companies:
Fibrocell Technologies
Castle Creek Pharmaceuticals
RHEACELL GmbH
RegeneRx
Amryt Pharma
Abeona Therapeutics
Krystal Biotech
And many others.
Epidermolysis Bullosa Therapies covered in the report includes:
FCX-007
CCP-020
RGN-137
AP-101
allo-APZ2-EB
EB-101
KB103
And many more.
Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/epidermolysis-bullosa-market
Table of Content
1. Key Insights
2. Executive Summary
3. Epidermolysis Bullosa Competitive Intelligence Analysis
4. Epidermolysis Bullosa Market Overview at a Glance
5. Epidermolysis Bullosa Disease Background and Overview
6. Epidermolysis Bullosa Patient Journey
7. Epidermolysis Bullosa Epidemiology and Patient Population
8. Epidermolysis Bullosa Treatment Algorithm, Current Treatment, and Medical Practices
9. Epidermolysis Bullosa Unmet Needs
10. Key Endpoints of Epidermolysis Bullosa Treatment
11. Epidermolysis Bullosa Marketed Products
12. Epidermolysis Bullosa Emerging Therapies
13. Epidermolysis Bullosa Seven Major Market Analysis
14. Attribute Analysis
15. Epidermolysis Bullosa Market Outlook (7 major markets)
16. Epidermolysis Bullosa Access and Reimbursement Overview
17. KOL Views on the Epidermolysis Bullosa Market.
18. Epidermolysis Bullosa Market Drivers
19. Epidermolysis Bullosa Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here: https://www.delveinsight.com/sample-request/epidermolysis-bullosa-market
Other Trending Healthcare Reports By DelveInsight
Follicular Lymphoma Market
DelveInsight’s “Follicular Lymphoma Market” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). As per DelveInsight, Follicular Lymphoma Market is expected to grow immensely in the coming years owing to the active participation of the key companies such as Epizyme, Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corporation, Bristol Myers Squibb, ADC Therapeutics, MorphoSys, Nordic Nanovector, AbbVie, Regeneron Pharmaceuticals, Janssen Research & Development, Novartis, MEI Pharma, BeiGene, and others.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
